Buzz-Drug maker Regeneron gains after upbeat Q2 results
REGN•Stock has lagged in 2026
As of the last close, REGN shares were down 9.9% year to date.
Earnings and revenue beat estimates
The company beat profit estimates for a fifth straight quarter, according to LSEG data.
Regeneron posted Q2 adjusted EPS of $14.3 versus analysts' estimate of $10.3, according to LSEG compiled data.
The company's Q2 revenue grew 17% to $4.29 billion versus an estimate of $3.82 billion.
Shares rise after strong quarterly results
Shares of drug maker Regeneron Pharmaceuticals REGN.O rose 5% premarket to $730.26 after second-quarter results beat estimates.
Q2 profit grew on higher sales of inflammatory diseases drug Dupixent and Eylea, an eye disease drug.
